Development of an RSV vaccine based on recombinant RSV-F expressed in mammalian cells and formulated in influenza virosomes

Font Standard Bold
Login

Research unit

INNOSUISSE

Project number

8082.1;5 LSPP-LS

Project title

Development of an RSV vaccine based on recombinant RSV-F expressed in mammalian cells and formulated in influenza virosomes

Texts for this project

	German	French	Italian	English
Short description	-	-	-
Abstract	-	-	-

Inserted texts

Category	Text
Short description (English)	Development of an RSV vaccine based on recombinant RSV-F expressed in mammalian cells and formulated in influenza virosomes
Abstract (English)	Respiratory syncytial virus (RSV) is one of the most important causes of viral lower respiratory tract illness (LRI) during early childhood. Pevion Biotech has shown that the RSV-F protein, when reconstituted in virosomes, induces neutralizing anti-F antibodies and does not cause pathology in mice as observed with other vaccine candidates. However, the protein yield from virus is low and hampered by safety concerns. Here the the development of an RSV vaccine from recombinant F protein expressed in mammalian cells is proposed. The F protein will be purified and incorporated into virosomes, and the vaccine will tested in animals.

Category

Text

Short description
(English)

Development of an RSV vaccine based on recombinant RSV-F expressed in mammalian cells and formulated in influenza virosomes

Abstract
(English)

Respiratory syncytial virus (RSV) is one of the most important causes of viral lower respiratory tract illness (LRI) during early childhood. Pevion Biotech has shown that the RSV-F protein, when reconstituted in virosomes, induces neutralizing anti-F antibodies and does not cause pathology in mice as observed with other vaccine candidates. However, the protein yield from virus is low and hampered by safety concerns. Here the the development of an RSV vaccine from recombinant F protein expressed in mammalian cells is proposed. The F protein will be purified and incorporated into virosomes, and the vaccine will tested in animals.